Similar articles

• Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.

  Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H. Chayama K, et al. Hepatology. 2012 Mar;55(3):742-8. doi: 10.1002/hep.24724. Epub 2012 Jan 30. Hepatology. 2012. PMID: 21987462 Clinical Trial.
• HCV NS5A inhibitors in development.

  Suk-Fong Lok A. Suk-Fong Lok A. Clin Liver Dis. 2013 Feb;17(1):111-21. doi: 10.1016/j.cld.2012.09.006. Clin Liver Dis. 2013. PMID: 23177287 Review.
• The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

  Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR. Zeuzem S, et al. Hepatology. 2012 Mar;55(3):749-58. doi: 10.1002/hep.24744. Hepatology. 2012. PMID: 22006408 Clinical Trial.
• HCV treatment--no more room for interferonologists?

  Drenth JP. Drenth JP. N Engl J Med. 2013 May 16;368(20):1931-2. doi: 10.1056/NEJMe1303818. Epub 2013 Apr 23. N Engl J Med. 2013. PMID: 23607592 No abstract available.
• Cyclophilin inhibitors for hepatitis C therapy.

  Membreno FE, Espinales JC, Lawitz EJ. Membreno FE, et al. Clin Liver Dis. 2013 Feb;17(1):129-39. doi: 10.1016/j.cld.2012.09.008. Clin Liver Dis. 2013. PMID: 23177289 Review.